287 related articles for article (PubMed ID: 23792009)
1. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
[TBL] [Abstract][Full Text] [Related]
3. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Laskin JJ; Nicholas G; Lee C; Gitlitz B; Vincent M; Cormier Y; Stephenson J; Ung Y; Sanborn R; Pressnail B; Nugent F; Nemunaitis J; Gleave ME; Murray N; Hao D
J Thorac Oncol; 2012 Mar; 7(3):579-86. PubMed ID: 22198426
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
8. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
9. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer.
Baykara M; Coskun U; Berk V; Ozkan M; Kaplan MA; Benekli M; Karaca H; Inanc M; Isikdogan A; Sevinc A; Elkiran ET; Demirci U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(10):5119-24. PubMed ID: 23244121
[TBL] [Abstract][Full Text] [Related]
11. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Hoang T; Dahlberg SE; Schiller JH; Johnson DH
Lung Cancer; 2013 Jul; 81(1):47-52. PubMed ID: 23611404
[TBL] [Abstract][Full Text] [Related]
12. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
13. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
14. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
[TBL] [Abstract][Full Text] [Related]
18. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Edelman MJ; Belani CP; Socinski MA; Ansari RH; Obasaju CK; Chen R; Monberg MJ; Treat J;
J Thorac Oncol; 2010 Jan; 5(1):110-6. PubMed ID: 20035187
[TBL] [Abstract][Full Text] [Related]
19. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
[TBL] [Abstract][Full Text] [Related]
20. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]